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a b s t r a c t
Regenerative medicine is a new and promising medical method aiming at treating patients with
defective or dysfunctional tissues by maintaining or enhancing the biological activity of cells. The
development of biomaterial-based technologies, such as cell scaffolds and carriers for drug delivery
system, are highly required to promote the regenerative research and regenerative therapy. Nucleic acids
are one of the most feasible factors to efficiently modify the biological activity of cells. The effective and
stable delivery of nucleic acids into cells is highly required to succeed in the modification. Biomaterials-
based non-viral carriers or biological carriers, like exosomes, play an important role in the efficient
delivery of nucleic acids. This review introduces the examples of regenerative research and regenerative
therapy based on the delivery of nucleic acids with biomaterials technologies and emphasizes their
importance to accomplish regenerative medicine.
© 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Regenerative medicine is to regenerate or repair the injured or
lost tissues and substitute organ functions by maintain or augment
the biological activity of cells in the site to be regenerated and
repaired. It is highly expected that the regenerative medicine may
resolve the problem of present advanced therapies, such as
reconstruction therapy and organ transplantation.
There are two fields in regenerative medicine; regenerative
research and regenerative therapy. The regenerative research
scientifically supports the next generation of regenerative ther-
apy and basically can be achieved through in vitro induction of
cellular activity. Regenerative research composes of two objec-
tives; the biological research of cells to make clear their activity
for tissue regeneration and the drug discovery to efficiently
evaluate drug action and toxicity with active cells. On the other
hand, the objective of regenerative therapy is to treat diseases
by the in vivo induction of cellular activity for tissue regenera-
tion. In these contexts, it is important to develop technologies
which enable to maintain or augment the biological activities of
cells necessary for both the regenerative research and regener-
ative therapy.
The biological activity of cells is modulated by their interaction
with bio-functional molecules and the surrounding microenvi-
ronment. For the successful modification of cellular biological ac-
tivity, it is highly required to allow cells to effectively interact with
bio-functional molecules and give good conditions for cells to
augment the activities. Technologies based on biomaterials, defined
as materials which are used contacting and interacting with the
biological components, play an important role in the artificial
modification of cellular biological activities for regenerative
medicine.
In the case of modification of cellular biological activities
by the bio-functional molecules, the biomaterials-based drug
delivery system (DDS) technology can be utilized aiming at the
effective delivery to the target cells. The objectives of DDS
include the controlled release, the life-time extension, the
accelerated permeation and absorption, and the targeting of
drug. All of DDS objectives are applicable for the modification
of cell biological activities based on the bio-functional mole-
cules. The bio-functional molecules include low-molecular-
weight substances, immune-stimulators, growth factors, anti-
gens, agonists, antagonists, diagnostic agents, imaging probes,
nucleic acids, and so on. The way how to interact with cells
for the biological modification depends on the type of bio-
functional molecules. For example, bio-signaling molecules of
growth factors modify the biological activity of cells through
the interaction with the receptors present on the surface of
cells, followed by the induction of signaling pathways. On the
other hand, several bio-functional molecules are required to be
internalized into cells and interacted with intracellular sub-
stances to modify the biological activities of cells. Therefore, it
is important to develop the DDS technology for the augmen-
tation of cellular biological activities considering the manner
of their interaction.
The biological activity of cells is also influenced by the
surrounding microenvironment. It is well recognized that cells
are present in the living tissue interacting with the extracel-
lular matrix (ECM), which induces various types of cellular
behaviors such proliferation, differentiation, and morphogen-
esis. Therefore, for the successful modification of cellular bio-
logical activities, it is indispensable to develop technologies to
give cells a local microenvironment similar to the ECM (arti-
ficial scaffold) by making use of biomaterials. It has been
demonstrated that the biological activity of cells is modified by
various characteristics of scaffolds, such as the charge, wetta-
bility, roughness, biological affinity of their surface or the
stiffness, porosity, and pore size of the bulk property [1e3].
The cell scaffolds of biomaterials are used alone or by
combining with the DDS technology.
In this review, nucleic acids of a bio-functional molecule to
modify the biological activity of cells are focused. The strategies and
examples of regenerative research and regenerative therapy based
on the delivery of nucleic acids with biomaterials technologies are
introduced to emphasize the importance of biomaterials-based
DDS to achieve regenerative medicine.
2. Nucleic acids for the biological modification of cell
activities
There are several types of nucleic acids which are involved in the
biological modification of cellular biological activity through the
regulation of cellular gene expression. The supplementation of
gene or the corresponding messenger RNA (mRNA) into cells can
increase the level of gene expression. On the other hand, the phe-
nomenon of RNA sequence-specific suppression of gene expression
level, so-called RNA interference (RNAi), has been discovered in
mammalian cells [4]. RNAi has been recognized as a phenomenon
that mRNA is sequence-specifically degraded by several small
double strand RNAs to suppress the biological activity of the cor-
responding protein. Based on the understanding of RNA interfering,
two main types of small RNAs such as small interfering RNAs
(siRNA) and microRNAs (miRNA) have been developed to suppress
the level of gene expression [5]. These RNAs form the RNA-induced
silencing complex (RISC) with Argonaute and other proteins, fol-
lowed by the binding to the target mRNA. The siRNA binds to the
target mRNA with the full complementarity and cleaves at the
10e12 bases from the 50 end of binding site. The miRNA bind to the
3’ untranslated region to inhibit the translation. Antisense oligo-
nucleotides have two mechanisms to suppress gene expression [6].
One is the hybridization to inhibit the role of ribosome, alter the
splicing, and inhibit the activity of ribonucleoprotein. The other is
the degradation of mRNA by the enzymes of RNase H and RISC. The
level of gene expression is also suppressed by a decoy of nucleic
acid with the same sequence for the interaction with the tran-
scription factor [7]. Taken together, various kinds of nucleic acids
enable cell to modify their biological activity via the regulation of
gene expression level.
It is well recognized that the nucleic acids in the naked form
cannot effectively exhibit their biological activities in the living
systems. A lot of technologies have been developed for the DDS
modification of nucleic acids. The general strategies on the design
of DDS for nucleic acids have been reviewed in various literature
[8e11]. The DDS strategy of nucleic acids to achieve regenerative
therapy and regenerative research is intensively introduced in the
following sections.
3. Strategies of regenerative research with nucleic acid
The objective of regenerative research is to create cells or their
constructs having high biological activities with biomaterials
in vitro and further develop the drug discovery and the basic
research of cell biology. Regenerative research with nucleic acids is
being proceeded based on the fact that the fate of cells is regulated
by nucleic acids which regulate the cellular gene expression (Fig. 1).
The efficient delivery of nucleic acids will be able to create cells
with interesting activities or elucidate molecular mechanisms un-
derlying the biological behavior of cells. For example, nucleic acids
reprogramming and differentiation technologies can genetically
engineer to create a disease cell by cell isolated from a disease
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patient [12]. Personalized drug discovery can be performed by us-
ing the disease cells created. In addition, recently, technologies to
create a 3-demensional (3D) tissue in vitro by combining cell with
the 3D scaffold of biomaterial have been actively developed
[13e15]. It has been demonstrated that the biological activities of
3D tissue-like cell constructs are high compared with those of
original cells [16e19]. There are many approaches for the 3D con-
struction of cells, which include cell aggregates, cell sheets, and cell
microfabrication. Combination of DDS-modified nucleic acids with
the 3D construct will further develop the research efficacy of drug
discovery and cell biology. The imaging technology based on
nucleic acids is also promising for the regenerative research.
Modification with genes encoding fluorescent or luminescent
proteins enables cells to demonstrate the distribution in the 3D
construct, which is useful for the validation of 3D construct. When
used in the drug discovery, the 3D construction of cells modified
with a gene encoding a fusion protein of fluorescent protein and
transcription factor, which is responsive to a biological phenome-
non, enables the biological evaluation against drug candidates in
the non-invasive manner.
4. Regenerative research based on nucleic acids of DDS
For the successful regenerative research with nucleic acids, it is
indispensable to develop methods to efficient deliver the nucleic
acid into cells of interest. Several biomaterials have been proposed
for DDS of nucleic acids, which include cationized polymers
[20e22], cationized liposomes [23e25], and ceramics [26]. How-
ever, since the biological expression of nucleic acids based on the
carriers is transient, it is not always suitable to effectively carry out
the regenerative research which is required to continue for long
time period. As one trial, an intracellular controlled release of
nucleic acid is considered to be promising.
We have prepared the nanoparticles of cationized gelatin
hydrogel to succeed in the controlled release of nucleic acids inside
cells [27]. The gene-carrying plasmid DNA incorporated in the
nanoparticles was released in the cells with their degradation.
When internalized into bone marrow-derived mesenchymal stem
cells, the cationized gelatin hydrogel nanoparticles were intracel-
lularly degraded with time and the plasmid DNA incorporated was
released in the controlled fashion. The time period of plasmid DNA
release depended on the degradation extent of nanoparticles. In
addition, this intracellular release technology with the cationized
gelatin nanoparticles also extended the duration of gene suppres-
sion of siRNA [28].
In addition to the intracellular controlled release technology, we
have applied a reverse transfection procedure established by
Sabatini et al. [29] for the regenerative research. In the conventional
procedure, transfection of nucleic acid is performed by adding
nucleic acid complexedwith a carrier to the culturemedium of cells
to be transfected. The reverse transfection is the transfection cul-
ture on the substrate immobilized nucleic acid complexed with a
carrier. It has been revealed that the reverse transfection procedure
has three advantages over the conventional transfection proced-
ures [30]. First, the reverse transfection procedure maintained a
high level of biological expression even in the presence of serum,
where the level was decreased by the conventional method. Next,
the biological expression of nucleic acid was extended by the
reverse transfection method to a significantly great extent
compared with that of the conventional method. Third, the cellular
viability after the reverse transfection method was significantly
higher than that by the conventional method. Considering the
procedure of reverse transfection, this transfection method can be
applied for the 3D culture substrate. We have succeeded in the
reverse transfection in/on a non-woven fabric of polyethylene
terephthalate [30], poly(D,L-lactic acid-co-glycolic acid) (PLGA)
scaffold [31], and gelatin sponge [32]. It is no doubt that the tech-
nology of transfection of nucleic acids in the 3D scaffold will
contribute the active promotion of regenerative research.
5. Strategies of regenerative therapy with nucleic acids
When the nucleic acid is applied for the regenerative therapy,





Cell biological research Drug discovery
Drug a Drug b Drug c Drug d ……..?
Cell scaffold
Fig. 1. The objective of regenerative research with nucleic acid is to effectively and stably deliver nucleic acids to cells or their 3D constructs in vitro by biomaterials-based DDS
technologies. Cells or their 3D constructs modified with nucleic acids enable to promote the cell biological research and drug discovery.
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desired. There are two approaches for the regenerative therapy
with nucleic acid (Fig. 2). One is to directly deliver nucleic acids to
cells present in the body. Types of cells to be delivered and nucleic
acids to deliver depend on the strategy of regenerative therapy. To
deliver the nucleic acids to tissue or stem cells which should be
proliferated or differentiated for cell-based tissue regeneration,
genes encoding the corresponding growth factors are used as a
nucleic acid [33]. Recently, it has been demonstrated that one or
several transcription factors or miRNA can control the fate of cells.
Especially, a biological phenomenon, called as “direct reprogram-
ing”, has been paid much attention. The direct reprogramming is
the direct conversion from a terminally-differentiated cells to ones
of different lineages. Many transcription factors and miRNA which
enable cells to induce the direct reprogramming, have been
discovered in various lineages [34]. The induction of “in vivo” direct
reprogramming allows fibroblasts of a body cell which do not al-
ways contribute to the cell-based tissue regeneration.
As described in the Introduction section, the regulation of cellular
microenvironment is crucial for cellular activity-based tissue
regeneration. For example, angiogenesis plays an important role in
tissue regeneration, because it enables cells to supply the oxygen and
nutrient to the tissue as well as remove the wastes from the tissue.
Many researches have been reported that the delivery of genes
encoding angiogenic growth factors promotes the tissue regenera-
tion [35]. In addition, recently much attention has been paid in the
regulation of inflammatory environment governed by immune cells
for the tissue regeneration [36]. Various types of immune cells, such
as dendritic cells, macrophages, monocytes, neutrophils, and T cells
etc., have been transfectedwith gene encoding factors affecting anti-
inflammatory environments [37e39].
Cells transplantation is one of the most feasible approaches for
the regeneration therapy since cells themselves have good thera-
peutic potentials in terms of their inherent targetability to the site
injured or biological properties. However, the therapeutic efficacy
of transplanted cells is not always as high as expected, which is one
of the largest problems in cell therapy. This is because the survival
ratio of transplanted cells is low, and consequently the biological
activities of cells are not always achieved in the body as strongly as
those expected from the in vitro activities. There are two ap-
proaches to tackle the problem by making use of nucleic acids. One
is to create an angiogenic or anti-inflammatory microenvironment
by the transfection of nucleic acids to resident cells as described
above. The other is to prepare cells biologically modified with
nucleic acids before their transplantation. Genes encoding humoral
factors to promote the tissue regeneration or reduce the suppres-
sion of cell biological activity associated with transplantation, have
been selected for nucleic acids [40e42].
The exosome is one of the extracellular vesicles secreted from
cells and includes various intracellular biomolecules, such as pro-
teins, lipids, and nucleic acids including non-coding RNAs, such as
miRNA and long non-codingRNAs (lncRNAs) [43,44]. The exosome
is advantageous over other genetic substances in terms of the
biological stability and specific information reflected to secreting
cells. In addition, recently the intercellular communication by the
exosome has been demonstrated [45e47]. In this context, the
exosome can be expected to be a genetic substances used for gene-
related therapeutic approaches [48]. Recently, trails on regenera-
tive therapy have been performed by making use of exosomes
obtained from somatic stem cells [49,50].
For successful cell therapy, it is indispensable to elucidate the
therapeutic mechanism of cells transplanted by utilizing imaging
technologies. Delivery of genes encoding fluorescent or lumines-
cent proteins and transporter proteins for the uptake of radioactive
substances has been performed to visualize and trace of cells
without any invasiveness [51,52].
6. Regenerative therapy based on nucleic acids of DDS
Nanoparticle-based carriers, biodegradable polymer-based car-
riers, and biological carriers, such as cells and exosomes [53e58],
have been mainly used to achieve regenerative therapy based on
nucleic acids. In this section, material design of these carriers and
concrete examples of regenerative therapy are introduced.
Since naked nucleic acids cannot always function in biological
systems, the active usage of DDS is highly required for the nucleic
acid-based regenerative therapy. There are two types of
Tissue regenerationDamaged tissue
Proliferation & differentiation












2’) Purification of exosomes 
Nucleic acids
Exosomes 
Fig. 2. There are two approaches for the regenerative therapy with nucleic acid; i) the direct delivery of nucleic acids to cells in vivo and ii) the transplantation of cells after
extraction and modification with nucleic acids or the injection of exosomes from cells extracted.
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administration procedures in regenerative medicine; local and
systemic administrations. So far, few researches have been per-
formed on the regenerative therapy based on the systemic
administration of nucleic acids combined with DDS. In the case of
local administration of nucleic acid, it is necessary to consider the
technology how to avoid the diffusion away from the injection site
and the degradation by nucleases. Complexation based on the
electrostatic interaction or encapsulation of nucleic acids with
biomaterial carriers has been explored as one trial to tackle these
problems. The large size of complexes and the steric hindrance of
biomaterial chains present on the surface of complexes can avoid
the diffusion away from the injection site and the degradation by
nucleases, respectively. For example, Uchida et al. have developed a
nanomicelle carrier for mRNA [59]. The nanomicelle has an mRNA-
containing inner core which is surrounded by the layer of poly-
ethylene glycol (PEG). The PEG chain of nanomicelle makes mRNA
stable even in the body. This nanomicelle system has been applied
for the regenerative therapy in the brain as well as cartilage [60,61].
In addition, polymeric nanoparticles and liposomes have been used
for the in vivo effective delivery of nucleic acid to achieve the tissue
regeneration [33,62e64].
When injected into the body, a nucleic acid in the solution form
rapidly diffused and disappeared from the injection site, resulting
in the decreased biological activity. Considering the regenerative
therapy based on the nucleic acid, the expression of biological ac-
tivity induced by the nucleic acid in the target cells is highly
required to maintain over several weeks or more. One of the
promising ways is to make the nucleic acid to remain around the
injection site and continuously act on the target cells. The
controlled release technology of DDS enables a nucleic acid to
maintain and release at the injection site in the controlled manner.
This technology can reduce the adverse effects by the single bolus
administration and the repeated administration. There are three
types of carriers for controlled release; non-biodegradable poly-
mers, biodegradable polymers, and ceramics. There are several
studies on controlled release of drug with non-biodegradable ma-
terials [65,66]. However, they are required to exclude after the
complete release of incorporated drug. On the other hand, various
biodegradable polymers have been used as carriers for the
controlled release of nucleic acids, such as poly(lactic acid) [67],
polyanhydride [68], poly(orthoester) [69], PLGA [70e80], poly(D,L-
lactide-co-4-hydroxy-L-proline) [81], poly(1,8-octanediol-co-cit-
rate) [82], oligo(poly(ethylene glycol) fumarate) [83], poly(2-
aminoethyl propylene phosphate) [84], polypseudorotaxane [85],
polysaccharide [86], silk elastin-like polymer [87], and atelocolla-
gen [88e90]. It has been reported that some ceramics, such as
calcium phosphate and calcium carbonates, are used for the
controlled release of nucleic acid [91,92]. By using the release sys-
tem of nucleic acids with the biodegradable polymers, the regen-
erative therapy for various tissues has been tried, such as the bone
formation [80,93], the recovery of spinal cord [78], and angiogen-
esis [86,94].
We have developed a cationized gelatin hydrogel as a carrier
for the controlled release of nucleic acid. Cationization of gelatin
was performed to electrostatically interact with the negatively-
charged nucleic acids. In the same fashion as other gelatin
hydrogels previously reported [95e97], the in vivo degradation of
gelatin hydrogels can be controlled by their crosslinking extents,
while the time profile of nucleic acid release was well corre-
sponded to that of hydrogel degradation [98]. Different from
other controlled release systems, nucleic acids are released from
the hydrogels in the state of complex with the cationized gelatin
fragments, which prevents the enzymatic degradation by nucle-
ases. Nucleic acids complexed with the cationized gelatin frag-
ments can be easily internalized into cells by the electrostatic
interaction with the negatively charged cell surface. As a result,
the augmented and extended biological expression of nucleic acid
was achieved by the cationized gelatin hydrogel. We have
confirmed that the profile of the hydrogel degradation and
release of nucleic acid is not influenced by the shape and size of
hydrogel [99]. So far, the controlled release system of nucleic
acids with the cationized gelatin hydrogels has succeeded in the
regeneration therapies for fibrosis [73,100e103], aortic aneu-
rysms [104], and autoimmune alopecia [105].
The genetic engineering of somatic stem cells is also one of the
promising approaches for regenerative therapy. Variousmethods to
genetically engineer somatic stem cells have been reported
[40e42]. Mesenchymal stem cells (MSC) of somatic stem cell, is a
promising cell source and has been used for the regeneration of
various tissues [106]. We have designed and prepared cationized
pullulan as a non-viral carrier of nucleic acid for MSC [107]. The
complexation with the cationized pullulan enabled a plasmid DNA
to augment the expression level of MSC to a significantly high
extent compared with that of LipofectAmine 2000® commercially
available. The genetic engineering of MSC by cationized pullulan
has demonstrated the efficient therapeutic effect for myocardiac
infarction [108], brain diseases [109], liver fibrosis [110], cartilage
regeneration [111], and wound repair [112,113].
7. Closing remarks and future perspectives
In this review, materials, technologies, and methodologies for
regenerative research and regenerative therapy by utilizing nucleic
acids were summarized. There have been reported on several ma-
terials and methodologies based on nucleic acids, which will be
useful and utilized in the future for regenerative research and
regenerative therapy.
Genome editing is a methodology to achieve the deletion and
insertion of specific sequence in the genome through the repair
mechanisms (non-homologous end joining, homologous recombi-
nation, etc.) after DNA double strand break by the artificial re-
striction enzymes [114]. The restriction enzymes include zinc-
finger nuclease (ZFN) [115], transcription activator-like effector
nuclease (TALEN) [116], and clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated systems (Cas)
(CRISPR/Cas) [117]. It is no doubt that the genome editing methods
will strongly contribute to the regenerative research.
Optogenetics are methodologies to control the biological activ-
ities of cells based on a light by the cellular expression of gene
encoding the light-responsive protein. It has been demonstrated
that the control of ion channel, second messenger, actin polymer-
ization, and gene expression was achieved by this method [118].
The spatial control of biological activity for cells by light is advan-
tageous over other methods. By utilizing this method, the prepa-
ration of 3D construct for the regenerative research, where
biological activities of cells are spatially regulated by light, might be
achieved.
With the progress of biology and chemistry on nucleic acid,
various functional nucleic acids, which can regulate or detect the
biological activities of cells through the specific interaction with
target endogenous nucleic acids (mRNA or miRNA), have been
easily designed and prepared. For example, Saito et al. have
developed a technology to regulate or detect the biological activ-
ities by artificially creating functional RNA or its complex of protein
[119,120]. The technology to estimate the sequence and structure of
nucleic acid necessary to interact with target nucleic acids has been
already established. By this advantage, the functional nucleic acids
to any target nucleic acid can be easily created. The versatile
functional nucleic acids will strongly support the regenerative
research.
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In future, the technological fusion of genome editing, opto-
genetics, and functional nucleic acids with DDS will achieve a new
strategy of regenerative medicine. It is no doubt that the DDS for
nucleic acids is crucial to promote regenerative research and
regenerative therapy. However, the DDS for nucleic acids is not
always perfect and has some rooms to be improved technologically
and methodologically. In fact, most of regenerative research and
regenerative therapy with nucleic acids have been carried out by
using viral carriers so far. For the promotion of regeneration
research and regeneration therapy to the clinical level, it would be
necessary to actively utilize the carriers of biomaterials which are
being used in clinics and derived from the body component, such as
extracellular vesicles [53e58], may become required. In addition, it
is important for several researchers with scientific backgrounds of
materials, chemicals, physics, biology, and informatics to develop a
new research field of regenerative medicine by efficient and sub-
stantial fusion to each other based on their own specialty.
Acknowledgement
The research is partly supported by the National Natural Science
Foundation of China (81620108028).
References
[1] Jafari M, Paknejad Z, Rad MR, Motamedian SR, Eghbal MJ, Nadjmi N, et al.
Polymeric scaffolds in tissue engineering: a literature review. J Biomed Mater
Res B Appl Biomater 2017;105(2):431e59.
[2] Ghasemi-Mobarakeh L, Prabhakaran MP, Tian L, Shamirzaei-Jeshvaghani E,
Dehghani L, Ramakrishna S. Structural properties of scaffolds: crucial pa-
rameters towards stem cells differentiation. World J Stem Cell 2015;7(4):
728e44.
[3] Carletti E, Motta A, Migliaresi C. Scaffolds for tissue engineering and 3D cell
culture. Methods Mol Biol 2011;695:17e39.
[4] Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 2001;411(6836):494e8.
[5] Davidson BL, McCray JrJr. Current prospects for RNA interference-based
therapies. Nat Rev Genet 2011;12(5):329e40.
[6] Braasch DA, Corey DR. Novel antisense and peptide nucleic acid strategies for
controlling gene expression. Biochemistry (Mosc) 2002;41(14):4503e10.
[7] Hecker M, Wagner AH. Transcription factor decoy technology: a therapeutic
update. Biochem Pharmacol 2017;144:29e34.
[8] Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral
vectors for gene-based therapy. Nat Rev Genet 2014;15(8):541e55.
[9] Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. Curr
Pharmaceut Biotechnol 2013;14(1):46e60.
[10] Ni R, Zhou J, Hossain N, Chau Y. Virus-inspired nucleic acid delivery system:
linking virus and viral mimicry. Adv Drug Deliv Rev 2016;106(Pt A):3e26.
[11] Bakhtiar A, Sayyad M, Rosli R, Maruyama A, Chowdhury EH. Intracellular
delivery of potential therapeutic genes: prospects in cancer gene therapy.
Curr Gene Ther 2014;14(4):247e57.
[12] Papp B, Plath K. Reprogramming to pluripotency: stepwise resetting of the
epigenetic landscape. Cell Res 2011;21(3):486e501.
[13] Peng W, Datta P, Ayan B, Ozbolat V, Sosnoski D, Ozbolat IT. 3D bioprinting for
drug discovery and development in pharmaceutics. Acta Biomater 2017;57:
26e46.
[14] Katakam P, Dey B, Assaleh FH, Hwisa NT, Adiki SK, Chandu BR, et al.
Top-down and bottom-up approaches in 3D printing technologies for
drug delivery challenges. Crit Rev Ther Drug Carrier Syst 2015;32(1):
61e87.
[15] Peck Y, Wang DA. Three-dimensionally engineered biomimetic tissue models
for in vitro drug evaluation: delivery, efficacy and toxicity. Expert Opin Drug
Deliv 2013;10(3):369e83.
[16] Kurosawa H. Methods for inducing embryoid body formation: in vitro dif-
ferentiation system of embryonic stem cells. J Biosci Bioeng 2007;103(5):
389e98.
[17] Fukuda J, Sakai Y, Nakazawa K. Novel hepatocyte culture system developed
using microfabrication and collagen/polyethylene glycol microcontact
printing. Biomaterials 2006;27(7):1061e70.
[18] Rodriguez-Enriquez S, Gallardo-Perez JC, Aviles-Salas A, Marin-Hernandez A,
Carreno-Fuentes L, Maldonado-Lagunas V, et al. Energy metabolism transi-
tion in multi-cellular human tumor spheroids. J Cell Physiol 2008;216(1):
189e97.
[19] Chen DY, Wei HJ, Lin WW, Lin KJ, Huang CC, Wu CT, et al. Intramuscular
delivery of 3D aggregates of HUVECs and cbMSCs for cellular car-
diomyoplasty in rats with myocardial infarction. J Control Release
2013;172(2):419e25.
[20] Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and
challenges. Prog Mol Biol Transl Sci 2011;104:509e62.
[21] Itaka K, Kataoka K. Progress and prospects of polyplex nanomicelles for
plasmid DNA delivery. Curr Gene Ther 2011;11(6):457e65.
[22] Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery.
Nucleic Acid Therapeut 2011;21(3):133e47.
[23] Xiong F, Mi Z, Gu N. Cationic liposomes as gene delivery system: transfection
efficiency and new application. Pharmazie 2011;66(3):158e64.
[24] Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and
polyplexes. Eur J Pharm Sci 2010;40(3):159e70.
[25] Ewert KK, Zidovska A, Ahmad A, Bouxsein NF, Evans HM, McAllister CS, et al.
Cationic liposome-nucleic acid complexes for gene delivery and silencing:
pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem
2010;296:191e226.
[26] Thomas SC, Harshita, Mishra PK, Talegaonkar S. Ceramic nanoparticles:
fabrication methods and applications in drug delivery. Curr Pharmaceut Des
2015;21(42):6165e88.
[27] Doi N, Jo JI, Tabata Y. Preparation of biodegradable gelatin nanospheres with
a narrow size distribution for carrier of cellular internalization of plasmid
DNA. J Biomater Sci Polym Ed 2011;23(8):991e1004.
[28] Ishikawa H, Nakamura Y, Jo J, Tabata Y. Gelatin nanospheres incorporating
siRNA for controlled intracellular release. Biomaterials 2012;33(35):
9097e104.
[29] Ziauddin J, Sabatini DM. Microarrays of cells expressing defined cDNAs.
Nature 2001;411(6833):107e10.
[30] Okazaki A, Jo JI, Tabata Y. A reverse transfection technology to genetically
engineer adult stem cells. Tissue Eng 2007;13(2):245e51.
[31] Miao PH, He CX, Hu YL, Tabata Y, Gao JQ, Hu ZJ. Impregnation of plasmid DNA
into three-dimensional PLGA scaffold enhances DNA expression of mesen-
chymal stem cells in vitro. Pharmazie 2012;67(3):229e32.
[32] Kido Y, Jo J, Tabata Y. A gene transfection for rat mesenchymal stromal cells
in biodegradable gelatin scaffolds containing cationized polysaccharides.
Biomaterials 2011;32(3):919e25.
[33] Fang YL, Chen XG, W TG. Gene delivery in tissue engineering and regener-
ative medicine. J Biomed Mater Res B Appl Biomater 2015;103(8):1679e99.
[34] Srivastava D, DeWitt N. In Vivo cellular reprogramming: the next generation.
Cell 2016;166(6):1386e96.
[35] Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regen-
eration. Exp Physiol 2005;90(3):315e26.
[36] Fatima F, Nawaz M. Nexus between extracellular vesicles, immunomodula-
tion and tissue remodeling: for good or for bad? Ann Transl Med 2017;5(6):
139.
[37] Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair
and regeneration. Science 2017;356(6342):1026e30.
[38] Smith TD, Nagalla RR, Chen EY, Liu WF. Harnessing macrophage plasticity for
tissue regeneration. Adv Drug Deliv Rev 2017;114:193e205.
[39] Dumont CM, Park J, Shea LD. Controlled release strategies for modulating
immune responses to promote tissue regeneration. J Control Release
2015;219:155e66.
[40] Nowakowski A, Walczak P, Lukomska B, Janowski M. Genetic engineering of
mesenchymal stem cells to induce their migration and survival. Stem Cell Int
2016;2016:4956063.
[41] Peng LH, Fung KP, Leung PC, Gao JQ. Genetically manipulated adult stem cells
for wound healing. Drug Discov Today 2011;16(21e22):957e66.
[42] Hodgkinson CP, Gomez JA, Mirotsou M, Dzau VJ. Genetic engineering of
mesenchymal stem cells and its application in human disease therapy. Hum
Gene Ther 2010;21(11):1513e26.
[43] Ela S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and
emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12(5):
347e57.
[44] Fatima F, Vesiculated MN. Long non-coding RNAs: offshore packages deci-
phering trans-regulation between cells, cancer progression and resistance to
therapies. Non-Coding RNA 2017;3(1).
[45] Robbins PD, Morelli AE. Regulation of immune responses by extracellular
vesicles. Nat Rev Immunol 2014;14(3):195e208.
[46] Mateescu B, Kowal EJ, van Balkom BW, Bartel S, Bhattacharyya SN,
Buzas EI, et al. Obstacles and opportunities in the functional analysis of
extracellular vesicle RNA - an ISEV position paper. J Extracell Vesicles
2017;6(1):1286095.
[47] Nawaz M, Fatima F, Vallabhaneni KC, Penfornis P, Valadi H, Ekstrom K, et al.
Extracellular vesicles: evolving factors in stem cell biology. Stem Cell Int
2016;2016:1073140.
[48] Fatima F, Ekstrom K, Nazarenko I, Maugeri M, Valadi H, Hill AF, et al. Non-
coding RNAs in mesenchymal stem cell-derived extracellular vesicles:
deciphering regulatory roles in stem cell potency, inflammatory resolve, and
tissue regeneration. Front Genet 2017;8:161.
[49] De Jong OG, Van Balkom BW, Schiffelers RM, Bouten CV, Verhaar MC.
Extracellular vesicles: potential roles in regenerative medicine. Front
Immunol 2014;5:608.
J.-i. Jo et al. / Regenerative Therapy 11 (2019) 123e130128
[50] Tan A, Rajadas J, Seifalian AM. Exosomes as nano-theranostic delivery plat-
forms for gene therapy. Adv Drug Deliv Rev 2013;65(3):357e67.
[51] Allport JR, Weissleder R. In vivo imaging of gene and cell therapies. Exp
Hematol 2001;29(11):1237e46.
[52] Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat
Rev Clin Oncol 2011;8(11):677e88.
[53] Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors.
Mol Ther 2009;17(5):767e77.
[54] Yeo RW, Lai RC, Zhang B, Tan SS, Yin Y, Teh BJ, et al. Mesenchymal stem cell:
an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv
Rev 2013;65(3):336e41.
[55] Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular
vesicles for genetic information transfer and gene therapy. Hum Mol Genet
2012;21(R1):R125e34.
[56] van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O,
Schiffelers RM. Extracellular vesicles as drug delivery systems: lessons from
the liposome field. J Control Release 2014;195:72e85.
[57] Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodel-
ing, tumor progression, and cancer immunotherapy. Chin J Canc
2015;34(12):541e53.
[58] Roma-Rodrigues C, Pereira F, Alves de Matos AP, Fernandes M, Baptista PV,
Fernandes AR. Smuggling gold nanoparticles across cell types - a new role for
exosomes in gene silencing. Nanomedicine 2017;13(4):1389e98.
[59] Uchida S, Itaka K, Uchida H, Hayakawa K, Ogata T, Ishii T, et al. In vivo
messenger RNA introduction into the central nervous system using polyplex
nanomicelle. PLoS One 2013;8(2):e56220.
[60] Lin CY, Perche F, Ikegami M, Uchida S, Kataoka K, Itaka K. Messenger RNA-
based therapeutics for brain diseases: an animal study for augmenting
clearance of beta-amyloid by intracerebral administration of neprilysin
mRNA loaded in polyplex nanomicelles. J Control Release 2016;235:268e75.
[61] Aini H, Itaka K, Fujisawa A, Uchida H, Uchida S, Fukushima S, et al. Messenger
RNA delivery of a cartilage-anabolic transcription factor as a disease-
modifying strategy for osteoarthritis treatment. Sci Rep 2016;6:18743.
[62] Galvez-Gastelum FJ, Garcia-Banuelos JJ, Beas-Zarate C, Segura-Flores A,
Gonzalez H, Chaparro-Huerta V, et al. Combinatorial gene therapy induces
regression of hepatic encephalopathy. Gene Ther 2011;18(1):88e94.
[63] Chu Z, Sun Y, Kuan CY, Grabowski GA, Qi X. Saposin C: neuronal effect and
CNS delivery by liposomes. Ann N Y Acad Sci 2005;1053:237e46.
[64] Huang YC, Simmons C, Kaigler D, Rice KG, Mooney DJ. Bone regeneration in a
rat cranial defect with delivery of PEI-condensed plasmid DNA encoding for
bone morphogenetic protein-4 (BMP-4). Gene Ther 2005;12(5):418e26.
[65] Kajihara M, Sugie T, Mizuno M, Tamura N, Sano A, Fujioka K, et al. Devel-
opment of new drug delivery system for protein drugs using silicone (I).
J Control Release 2000;66(1):49e61.
[66] Thakral S, Thakral NK, Majumdar DK. Eudragit: a technology evaluation.
Expert Opin Drug Deliv 2013;10(1):131e49.
[67] Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ
tumor vaccination with interleukin-12-encapsulated biodegradable micro-
spheres: induction of tumor regression and potent antitumor immunity.
Cancer Res 2000;60(14):3832e7.
[68] Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, et al.
Biologically erodable microspheres as potential oral drug delivery systems.
Nature 1997;386(6623):410e4.
[69] Nguyen DN, Raghavan SS, Tashima LM, Lin EC, Fredette SJ, Langer RS, et al.
Enhancement of poly(orthoester) microspheres for DNA vaccine delivery by
blending with poly(ethylenimine). Biomaterials 2008;29(18):2783e93.
[70] Wang D, Robinson DR, Kwon GS, Samuel J. Encapsulation of plasmid DNA in
biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel
approach for immunogene delivery. J Control Release 1999;57(1):9e18.
[71] Tinsley-Bown AM, Fretwell R, Dowsett AB, Davis SL, Farrar GH. Formulation
of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA
delivery. J Control Release 2000;66(2e3):229e41.
[72] Cohen H, Levy RJ, Gao J, Fishbein I, Kousaev V, Sosnowski S, et al. Sustained
delivery and expression of DNA encapsulated in polymeric nanoparticles.
Gene Ther 2000;7(22):1896e905.
[73] Stern M, Ulrich K, Geddes DM, Alton EW. Poly (D, L-lactide-co-glycolide)/
DNA microspheres to facilitate prolonged transgene expression in airway
epithelium in vitro, ex vivo and in vivo. Gene Ther 2003;10(16):1282e8.
[74] Chun KW, Cho KC, Kim SH, Jeong JH, Park TG. Controlled release of plasmid
DNA from biodegradable scaffolds fabricated using a thermally-induced
phase-separation method. J Biomater Sci Polym Ed 2004;15(11):1341e53.
[75] Diez S, Tros de Ilarduya C. Versatility of biodegradable poly(D,L-lactic-co-
glycolic acid) microspheres for plasmid DNA delivery. Eur J Pharm Bio-
pharm 2006;63(2):188e97.
[76] Intra J, Salem AK. Rational design, fabrication, characterization and in vitro
testing of biodegradable microparticles that generate targeted and sustained
transgene expression in HepG2 liver cells. J Drug Target 2011;19(6):
393e408.
[77] Chen M, Gao S, Dong M, Song J, Yang C, Howard KA, et al. Chitosan/siRNA
nanoparticles encapsulated in PLGA nanofibers for siRNA delivery. ACS Nano
2012;6(6):4835e44.
[78] Lowry N, Goderie SK, Lederman P, Charniga C, Gooch MR, Gracey KD, et al.
The effect of long-term release of Shh from implanted biodegradable mi-
crospheres on recovery from spinal cord injury in mice. Biomaterials
2012;33(10):2892e901.
[79] Needham CJ, Shah SR, Mountziaris PM, Kasper FK, Mikos AG. Modulation of
polyplex release from biodegradable microparticles through poly(-
ethylenimine) modification and varying loading concentration. Pharm Res (N
Y) 2014;31(1):77e85.
[80] Qiao C, Zhang K, Jin H, Miao L, Shi C, Liu X, et al. Using poly(lactic-co-glycolic
acid) microspheres to encapsulate plasmid of bone morphogenetic protein 2/
polyethylenimine nanoparticles to promote bone formation in vitro and
in vivo. Int J Nanomed 2013;8:2985e95.
[81] Li Z, Huang L. Sustained delivery and expression of plasmid DNA based on
biodegradable polyester, poly(D,L-lactide-co-4-hydroxy-L-proline). J Control
Release 2004;98(3):437e46.
[82] Zhang XQ, Tang H, Hoshi R, De Laporte L, Qiu H, Xu X, et al. Sustained
transgene expression via citric acid-based polyester elastomers. Biomaterials
2009;30(13):2632e41.
[83] Kasper FK, Seidlits SK, Tang A, Crowther RS, Carney DH, Barry MA, et al.
In vitro release of plasmid DNA from oligo(poly(ethylene glycol) fumarate)
hydrogels. J Control Release 2005;104(3):521e39.
[84] Wang J, Zhang PC, Mao HQ, Leong KW. Enhanced gene expression in mouse
muscle by sustained release of plasmid DNA using PPE-EA as a carrier. Gene
Ther 2002;9(18):1254e61.
[85] Li Z, Yin H, Zhang Z, Liu KL, Li J. Supramolecular anchoring of DNA polyplexes
in cyclodextrin-based polypseudorotaxane hydrogels for sustained gene
delivery. Biomacromolecules 2012;13(10):3162e72.
[86] Kong HJ, Kim ES, Huang YC, Mooney DJ. Design of biodegradable hydrogel for
the local and sustained delivery of angiogenic plasmid DNA. Pharm Res (N Y)
2008;25(5):1230e8.
[87] Gustafson J, Greish K, Frandsen J, Cappello J, Ghandehari H. Silk-elastinlike
recombinant polymers for gene therapy of head and neck cancer: from
molecular definition to controlled gene expression. J Control Release
2009;140(3):256e61.
[88] Ochiya T, Nagahara S, Sano A, Itoh H, Terada M. Biomaterials for gene de-
livery: atelocollagen-mediated controlled release of molecular medicines.
Curr Gene Ther 2001;1(1):31e52.
[89] Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, et al. New
delivery system for plasmid DNA in vivo using atelocollagen as a carrier
material: the Minipellet. Nat Med 1999;5(6):707e10.
[90] Sano A, Maeda M, Nagahara S, Ochiya T, Honma K, Itoh H, et al. Atelocollagen
for protein and gene delivery. Adv Drug Deliv Rev 2003;55(12):1651e77.
[91] Choi S, Murphy WL. Sustained plasmid DNA release from dissolving mineral
coatings. Acta Biomater 2010;6(9):3426e35.
[92] Uskokovic V, Uskokovic DP. Nanosized hydroxyapatite and other calcium
phosphates: chemistry of formation and application as drug and gene
delivery agents. J Biomed Mater Res B Appl Biomater 2011;96(1):
152e91.
[93] Chew SA, Kretlow JD, Spicer PP, Edwards AW, Baggett LS, Tabata Y, et al.
Delivery of plasmid DNA encoding bone morphogenetic protein-2 with a
biodegradable branched polycationic polymer in a critical-size rat cranial
defect model. Tissue Eng 2011;17(5e6):751e63.
[94] Kasahara H, Tanaka E, Fukuyama N, Sato E, Sakamoto H, Tabata Y, et al.
Biodegradable gelatin hydrogel potentiates the angiogenic effect of fibroblast
growth factor 4 plasmid in rabbit hindlimb ischemia. J Am Coll Cardiol
2003;41(6):1056e62.
[95] Ozeki M, Tabata Y. In vivo degradability of hydrogels prepared from different
gelatins by various cross-linking methods. J Biomater Sci Polym 2005;16(5):
549e61.
[96] Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the
controlled release of bioactive molecules. J Control Release 2005;109(1e3):
256e74.
[97] Tabata Y. Biomaterial technology for tissue engineering applications. J R Soc
Interface 2009;6(Suppl 3):S311e24.
[98] Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. Controlled release
of plasmid DNA from cationized gelatin hydrogels based on hydrogel
degradation. J Control Release 2002;80(1e3):333e43.
[99] Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of the prog-
ress of disseminated pancreatic cancer cells by NK4 plasmid DNA released
from cationized gelatin microspheres. Pharm Res (N Y) 2004;21(7):1109e18.
[100] Aoyama T, Yamamoto S, Kanematsu A, Ogawa O, Tabata Y. Local delivery of
matrix metalloproteinase gene prevents the onset of renal sclerosis in
streptozotocin-induced diabetic mice. Tissue Eng 2003;9(6):1289e99.
[101] Lin X, Jo H, Ishii TM, Fujita M, Fu M, Tambara K, et al. Controlled release of
matrix metalloproteinase-1 plasmid DNA prevents left ventricular remod-
eling in chronic myocardial infarction of rats. Circ J 2009;73(12):2315e21.
[102] Wu TH, Hsu SH, Chang MH, Huang YY. Reducing scar formation by regulation
of IL-1 and MMP-9 expression by using sustained release of prednisolone-
loaded PDLL microspheres in a murine wound model. J Biomed Mater Res
A 2013;101(4):1165e72.
[103] Xia Z, Abe K, Furusu A, Miyazaki M, Obata Y, Tabata Y, et al. Suppression of
renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock
protein 47. Am J Nephrol 2008;28(1):34e46.
[104] Zhong H, Matsui O, Xu K, Ogi T, Sanada J, Okamoto Y, et al. Gene transduction
into aortic wall using plasmid-loaded cationized gelatin hydrogel-coated
polyester stent graft. J Vasc Surg 2009;50(6):1433e43.
[105] Nakamura M, Jo J, Tabata Y, Ishikawa O. Controlled delivery of T-box21 small
interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a
C3H/HeJ mouse model. Am J Pathol 2008;172(3):650e8.
J.-i. Jo et al. / Regenerative Therapy 11 (2019) 123e130 129
[106] Rohban R, Pieber TR. Mesenchymal stem and progenitor cells in regenera-
tion: tissue specificity and regenerative potential. Stem Cell Int 2017;2017:
5173732.
[107] Jo J, Tabata Y. Non-viral gene transfection technologies for genetic engi-
neering of stem cells. Eur J Pharm Biopharm 2008;68(1):90e104.
[108] Jo J, Nagaya N, Miyahara Y, Kataoka M, Harada-Shiba M, Kangawa K,
et al. Transplantation of genetically engineered mesenchymal stem cells
improves cardiac function in rats with myocardial infarction: benefit of
a novel nonviral vector, cationized dextran. Tissue Eng 2007;13(2):
313e22.
[109] Huang B, Tabata Y, Gao JQ. Mesenchymal stem cells as therapeutic agents
and potential targeted gene delivery vehicle for brain diseases. J Control
Release 2012;162(2):464e73.
[110] Ishikawa H, Jo J, Tabata Y. Liver anti-fibrosis therapy with mesenchymal stem
cells secreting hepatocyte growth factor. J Biomater Sci Polym Ed
2012;23(18):2259e72.
[111] He CX, Zhang TY, Miao PH, Hu ZJ, Han M, Tabata Y, et al. TGF-beta1 gene-
engineered mesenchymal stem cells induce rat cartilage regeneration us-
ing nonviral gene vector. Biotechnol Appl Biochem 2012;59(3):163e9.
[112] Peng LH, Mao ZY, Qi XT, Chen X, Li N, Tabata Y, et al. Transplantation of bone-
marrow-derived mesenchymal and epidermal stem cells contribute to
wound healing with different regenerative features. Cell Tissue Res
2013;352(3):573e83.
[113] Nakamura Y, Ishikawa H, Kawai K, Tabata Y, Suzuki S. Enhanced wound
healing by topical administration of mesenchymal stem cells transfected
with stromal cell-derived factor-1. Biomaterials 2013;34(37):9393e400.
[114] Hu JH, Davis KM, Liu DR. Chemical biology approaches to genome editing:
understanding, controlling, and delivering programmable nucleases. Cell
Chem Biol 2016;23(1):57e73.
[115] Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing gene targeting
with designed zinc finger nucleases. Science 2003;300(5620):764.
[116] Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA
targeting. Science 2011;333(6051):1843e6.
[117] Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome
engineering using CRISPR/Cas systems. Science 2013;339(6121):819e23.
[118] Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-time-
scale, genetically targeted optical control of neural activity. Nat Neurosci
2005;8(9):1263e8.
[119] Karagiannis P, Fujita Y, Saito H. RNA-based gene circuits for cell regulation.
Proc Jpn Acad Ser B Phys Biol Sci 2016;92(9):412e22.
[120] Ohno H, Saito H. RNA and RNP as building blocks for nanotechnology and
synthetic biology. Prog Mol Biol Transl Sci 2016;139:165e85.
J.-i. Jo et al. / Regenerative Therapy 11 (2019) 123e130130
